GAITHERSBURG, Md., Jan. 14 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, and Lentigen Corporation, a privately-owned biotechnology company focused on the manufacture and development of lentiviral vectors, today announced that they have agreed to settle the pending litigation between the two companies. The parties will dismiss all claims and counterclaims asserted in the lawsuit, which has been pending in the Circuit Court for Baltimore County in Maryland. Additional terms and conditions of the settlement are confidential.
About VIRxSYS
VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company’s initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company’s laboratories. The RNA payload technology was acquired and has been integrated with the Company’s lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which has advanced to Phase II human clinical trials. More information regarding VIRxSYS can be found at www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.
About Lentigen Corporation
Lentigen Corporation is a privately-owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit www.lentigen.com.
pgibney@corinthgroup.comgtiberend@rlcinc.com
CONTACT: Paul Gibney of Corinth Group Communications, +1-212-255-5340,
pgibney@corinthgroup.com; or Gregory Tiberend of Richard Lewis
Communications, Inc., +1-212-827-0020, gtiberend@rlcinc.com, both of
VIRxSYS Corporation and Lentigen Corporation
Web site: http://www.lentigen.com/
http://www.virxsys.com/
http://clinicaltrials.gov/show/NCT00131560/
